Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Multiple myeloma, gammopathies

Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014

Leukemia volume 32, pages 2054–2057 (2018)Cite this article

Subjects

Despite the introduction of proteasome inhibitor (PI) and immunomodulatory drugs (IMiDs) as induction treatment some patients still experience early relapse after autologous hematopoietic bone marrow transplantation (HDM-ASCT) and these patients have poor outcome [1,2,3,4]. Few studies have addressed early relapse after HDM-ASCT as a risk marker for poor overall survival (OS). Kumar et al. found an OS of 20.1 months for patients with a relapse within 1 year following VAD or thalidomide as induction treatment [5] and OS was only 23.1 months among patients who received induction treatment with IMiDs and PI [3]. In 2010, we found an OS of 28.7 months for patients with relapse within 18 months from HDM-ASCT before induction treatment with PI and IMiDs [2].

The aim of this study was to analyze outcome and prognostic markers for OS in patients with an early relapse after HDM-ASCT in a population-based cohort of multiple myeloma (MM) patients before and after IMiDs and PI was used as induction and relapse treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, et al. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol. 2010;85:209–16.

    Article  PubMed  CAS  Google Scholar 

  3. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015;50:204–8.

    Article  PubMed  CAS  Google Scholar 

  5. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42:413–20.

    Article  PubMed  CAS  Google Scholar 

  6. Gimsing P, Holmstrom MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;8:583–7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol. 2017;179:198–218.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The work was funded by The Research Fund at Rigshospitalet, Copenhagen, Denmark and The Danish Cancer Society, Copenhagen, Denmark R152-A9822-16-S7.

Author information

Authors and Affiliations

  1. Department of Hematology, Rigshospitalet, Copenhagen, Denmark

    Sissel Helm-Petersen, Rasmus Sørrig, Peter Gimsing & Annette J. Vangsted

  2. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Rasmus Sørrig

  3. Hematological Research Laboratory, Herlev Hospital, Herlev, Denmark

    Tobias W. Klausen

  4. Department of Pathology, Odense University Hospital, Odense, Denmark

    Birgitte Preiss

  5. Department of Hematology, Roskilde Hospital, Roskilde, Denmark

    Ulf Christian Frølund

  6. Department of Hematology, Herlev Hospital, Herlev, Denmark

    Carsten Helleberg

  7. Department of Pathology, Herlev Hospital, Herlev, Denmark

    Marie Breinholt

  8. Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark

    Mette Klarskov Andersen

  9. Department of Hematology, Odense University Hospital, Odense, Denmark

    Niels Abildgaard

Authors
  1. Sissel Helm-Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rasmus Sørrig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias W. Klausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Birgitte Preiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulf Christian Frølund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carsten Helleberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie Breinholt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mette Klarskov Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Niels Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter Gimsing
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Annette J. Vangsted
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette J. Vangsted.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

41375_2018_57_MOESM1_ESM.docx

Early relapsed disease of multiple myeloma following up-front HDM-ASCT. A study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Helm-Petersen, S., Sørrig, R., Klausen, T.W. et al. Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia 32, 2054–2057 (2018). https://doi.org/10.1038/s41375-018-0057-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0057-5

This article is cited by

Search

Advanced search

Quick links